QQ客服 官方微博 反馈留言

	Corrigendum to "A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study" [J. Pharm
	Yao Xueting; Song Ling; Liu Yang; Wang Huanhuan; Liu Jie; Jiang Ji; Liu Dongyang; Hu Pei
	2019
ISSN号	1873-264X
DOI	10.1016/j.jpba.2019.04.047
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6338353
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yao Xueting,Song Ling,Liu Yang,et al. Corrigendum to "A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study" [J. Pharm[J],2019.
APA	Yao Xueting.,Song Ling.,Liu Yang.,Wang Huanhuan.,Liu Jie.,...&Hu Pei.(2019).Corrigendum to "A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study" [J. Pharm..
MLA	Yao Xueting,et al."Corrigendum to "A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study" [J. Pharm".(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。